This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a section to host genetics in other clinical situations, such as disease progression and acute HCV infection, which may determine whether treatment of HIV-/HCV-coinfected patients is implemented or deferred.
Keywords: DAA; HCV; HIV; HLA; IFNL3; IFNL4; KIR; PegIFN/RBV; SNP; SVR; adverse events; fibrosis; pharmacogenetics; spontaneous resolution.